The Science of Sample Size: Statistical Strategies in Ziftomenib and Revumenib Trials
Analyzing how two groundbreaking menin inhibitors utilized different statistical frameworks—Exact Binomial Distribution vs. Simon's Two-Stage Design—to optimize their clinical trial trajectories.
1. The Crucial Role of Sample Size in Clinical Oncology
In the development of novel targeted therapies for acute myeloid leukemia (AML), calculating the appropriate sample size is not merely a mathematical exercise; it is a profound strategic decision. Enroll too few patients, and the trial lacks the statistical power to prove efficacy. Enroll too many, and the sponsor wastes invaluable time, resources, and potentially exposes more patients than necessary to an ineffective experimental drug. Recently, the development of two novel menin inhibitors—Ziftomenib and Revumenib—provided a fascinating masterclass in how statistical trial design is tailored to the specific phase and strategic goals of the drug's development.
2. Ziftomenib: The Exact Binomial Distribution Approach
Ziftomenib was evaluated in the KOMET-001 trial, specifically focusing on its registration-enabling Phase II portion for patients with relapsed/refractory NPM1-mutated (NPM1-m) AML. Because this portion of the trial was designed as a definitive, single-arm Phase II study aiming for accelerated approval, the researchers required a fixed, robust sample size to confidently demonstrate superiority over historical standards.
To achieve this, the statisticians utilized an Exact Binomial Distribution test. The historical standard-of-care complete remission (CR/CRh) rate for this heavily pretreated population was a dismal 12%. The trial was designed to test the hypothesis that Ziftomenib could achieve a 25% expected response rate. Using an exact binomial calculation (via EAST software), they determined that enrolling at least 85 patients would provide 89% statistical power to detect this difference, assuming a stringent one-sided alpha level of 0.025. This "fixed-N" approach is highly appropriate when the safety profile and preliminary efficacy are already well-understood from a preceding Phase I study, allowing the sponsor to commit fully to the target enrollment without planned early stopping for futility.
3. Revumenib: Simon's Two-Stage Design for Rapid Go/No-Go
In contrast, Revumenib was evaluated in the AUGMENT-101 trial, which was designed as a seamless Phase I/II study treating patients with relapsed/refractory KMT2A-rearranged (KMT2Ar) acute leukemia. Because Phase I and II were integrated, the sponsor needed a flexible statistical mechanism to quickly halt the trial if the drug proved ineffective in Phase II, thereby saving resources and protecting patients.
To solve this, the researchers employed the minimax version of Simon's Two-Stage Design. They set a null hypothesis of a 10% CR+CRh rate against an alternative (target) rate of 25%, aiming for 90% power and a 2.5% one-sided significance level. Simon's minimax design split the enrollment into two distinct phases:
- Stage 1 (Interim Analysis): The trial first enrolled 38 efficacy-evaluable adult patients. The rule was strict: if fewer than 5 patients (out of 38) responded, the trial would be immediately terminated for futility.
- Stage 2: If 5 or more patients responded in Stage 1, the trial would get a "Go" decision and continue enrollment until reaching a total of 64 evaluable adult patients to confirm the final efficacy.
💡 My Practical Perspective: Strategic Judgment in Trial Design
In clinical trials, there is no single "correct" method for determining sample size; rather, it is a matter of strategic judgment based on the specific stage of the drug's pipeline.
Revumenib utilized a Simon's two-stage design (minimax) because it was a seamless Phase 1/2 study. This approach is a highly efficient "Go/No-go" strategy, allowing the sponsor to perform an interim analysis with a minimal initial cohort (38 patients). It enables rapid termination if the drug lacks efficacy, thereby conserving resources and protecting patients from unnecessary exposure.
Conversely, Ziftomenib was positioned for a registration-enabling Phase II trial aimed at definitive FDA approval. Instead of an early-stopping strategy, they employed an Exact Binomial Distribution to ensure robust statistical power from the outset, committing to a fixed cohort of 85 patients. As demonstrated here, even for drugs with the same mechanism (Menin inhibitors), the statistical framework must be tailored precisely to the trial's regulatory objectives and clinical phase.